Should high hTg levels in the absence of iodine uptake be treated? [1]

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 30, Issue 5, 2003, Pages 794-795

  Britton, K E ^a   Foley, R R ^a   Chew, S L ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; DIAGNOSTIC AGENT; ETHER DERIVATIVE; ETIDRONIC ACID RE 186; IODINE; IODINE 123; IODINE 131; LIOTHYRONINE; MEDRONATE TECHNETIUM TC 99M; PENTETREOTIDE IN 111; THYROGLOBULIN; THYROTROPIN; TRACER; YTTRIUM 90;

BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL PROTOCOL; DIAGNOSTIC IMAGING; DRUG UPTAKE; ESOPHAGUS; FOLLOW UP; HIGH RISK POPULATION; HORMONAL REGULATION; HUMAN; IONIZING RADIATION; LETTER; PILOT STUDY; QUANTITATIVE ANALYSIS; RADIOISOTOPE THERAPY; SALIVA; SCINTILLATION CAMERA; SWALLOWING; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROID SCINTISCANNING;

EID: 0037569468     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-003-1139-8     Document Type: Letter

References (12)

1. Lind P. Should high hTg levels in the absence of iodine uptake be treated? For. Eur J Nucl Med Mol Imaging 2003; 30:157-160.
2. Biermann M, Schober O. Should high hTg levels in the absence of iodine uptake be treated? Against. Eur J Nucl Med Mol Imaging 2003; 30:160-163.
3. Britton KE, Granowska M. Radioimmunoscintigraphy in tumour identification. Cancer Surv 1987; 6:247-267.
4. Britton KE, Foley RR, Siddiqi A, et al. I-123 imaging for the prediction of I-131 therapy for recurrent differentiated thyroid cancer, RDTC, when I-131 tracer is negative but raised. Eur J Nucl Med 1999; 26:1013.
5. Siddiqui A, Foley RR, Britton KE, et al. The role of I-123 diagnostic maging in the follow up of patients with differentiated thyroid carcinoma as compared to I-131-scanning: avoidance of negative therapeutic uptake due to stunning. Clin Endocrinol 2001; 55:515-521.
6. Maxon HR III, Thomas SR, Washburne LC, et al. High activity I-123 for the diagnostic evaluation of patients with thyroid cancer. J Nucl Med 1993; 25:242-246.
7. Gulzar Z, Jana S, Young I, et al. Neck and whole-body scanning with a 5 mCi dose of I-123 as diagnostic tracer in patients with well differentiated thyroid cancer. Endocrine Practice 2001; 7:244-249.
8. Kalinyak JE. I-123 as a diagnostic tracer in the management of thyroid cancer. Nucl Med Commun 2002; 23:509-511.
9. Leger FA, Izembart M, Dagousset F, et al. Decreased uptake of therapeutic doses of I-131 after 185 MBq I-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med 1998; 25:242-246.
10. Sarkar SD, Kalapparabath TP, Palestro CJ. Comparison of I-123 and I-131 for whole body imaging and thyroid cancer. J Nucl Med 2002; 43:632-634.
11. Shankar LK, Yamamoto AJ, Alavi IA, Mandel SJ. Comparison of I-123 scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer. J Nucl Med 2002; 43:72-76.
12. Park HM. Invited commentary: I-123 almost a designer radio-iodine for thyroid scanning. J Nucl Med 2002; 43:77-78.